|IACP Meets with Congress|
Cynthia Blankenship, who is employed by Rose Law Firm and recently rejoined IACP, and David Pore of Arnold and Porter, IACP's DC legislative counsel, went to the Hill to meet with Congress last week on behalf of compounding pharmacists.
Congress' recently passed Omnibus bill includes language requested by IACP members that mandates FDA to issue guidance within 90 days allowing office-use compounding, prohibits FDA from restricting dispensing practices under the MOU, and mandates FDA to report to Congress within 90 days regarding the finalization of the positive bulk ingredient lists. Cynthia and David met with Appropriators to thank them for continuing to be champions for compounding pharmacists.
The Senate Appropriations Committee also was successful in denying all FDA's requests for increased funding in implementing the DQSA compounding provisions. This language could not have been possible without the dedication of our Congressional champions.
Your IACP Board of Directors, led by your current Chairman and President, Dale Coker, RPh, FIACP, and Gary McCrory, RPh, CCN, respectively, worked diligently to monitor this issue, designated this appropriations language as a top priority and provided examples and data needed by Congress.
The IACP Legislative Committee, led by Erik Tosh, BS, RPh, FIACP, FACA, worked around the clock to provide input and edits to proposed language and act as a resource to Congress. For a full description of the language included in the Omnibus Appropriations language, please click here.
The letter was signed by more than a dozen pharmacy and physician national organizations as well as more than 20 State Boards of Pharmacy. The letters were sent via mail to all State Boards of Pharmacy and Medicine this past week.
Please click here to view a final letter to State Boards of Pharmacy and Medicine.
Please click here to view IACP's press release on this effort.
The DQSA Coalition will continue working on this issue and has agreed to send a letter regarding the Omnibus language to both FDA and Congress. The DQSA Coalition currently is undertaking efforts to draft these letters with the intent of finalizing in the next week.
The Coalition also will be acting as a resource to Congress as Congress sends a letter to FDA on this issue. The DQSA Coalition continues to grow in size with more organizations joining last week. It now includes 30 organizations representing physician, pharmacy, and patient concerns.
Tell us how compounded pharmaceuticals have helped you, someone you know, or how you have helped someone as a practicing compounding pharmacist. Help us protect your continued access to pharmacy compounding!
Share the P3 community and the value and necessity of personalized prescriptions with your friends.